Global Biosimilar Markets: Europe vs United States in 2026

Have you ever wondered why the same life-saving drug costs a fortune in one country but is affordable in another? The answer often lies in biosimilars. These are not just cheaper versions of drugs; they are complex biological products that have revolutionized healthcare economics. But here is the twist: the story of biosimilars is not the same everywhere. In fact, if you look at Europe and the United States, you see two completely different chapters of the same book.

In 2026, the gap between these two giants is closing, but the scars of the past remain. Europe has been playing this game for nearly two decades, building a mature ecosystem where doctors and patients trust these alternatives. The US, on the other hand, spent years stuck in legal limbo before finally waking up to the potential savings. Today, we are seeing a massive shift. With new regulations and patent cliffs hitting hard, the US market is accelerating fast. But does it catch up to Europe’s level of adoption? Let’s break down what is really happening behind the scenes.

The Tale of Two Regulatory Paths

To understand why the markets differ, you have to look at how they started. It all comes down to rules. The European Medicines Agency (EMA) was the pioneer. Back in 2006, they approved the world’s first biosimilar, Omnitrope. They took a pragmatic approach: if the data shows the drug is highly similar to the original with no clinically meaningful differences, let it in. This "totality-of-evidence" method required less clinical trial data compared to what the US demanded initially.

Then there is the Food and Drug Administration (FDA) in the United States. While the Biologics Price Competition and Innovation Act (BPCIA) was passed in 2009 as part of the Affordable Care Act, the first US biosimilar, Zarxio, didn’t hit the market until March 2015. Why the delay? The US system was designed with heavy safeguards, including a complex process known as the "patent dance." This allowed originator companies to file lawsuits and block competition for years. For a long time, the US required extensive clinical trials and switching studies to prove a biosimilar was "interchangeable," creating a high barrier to entry that discouraged many manufacturers.

However, the wind changed in June 2024. The FDA proposed new guidelines eliminating the requirement for switching studies to achieve interchangeable designation. Dr. Rachel Sherman from the FDA acknowledged that previous requirements created unnecessary barriers. This move signals a major shift toward the European model, aiming to accelerate competition and lower costs for American patients.

Market Size and Growth Trajectories

When we talk numbers, the picture gets interesting. Europe has historically held the crown for market share. According to Alira Health’s 2025 Global Biosimilars Report, the European market reached approximately USD 13.16 billion in 2024. It grew steadily from USD 8.9 billion in 2020, showing a compound annual growth rate (CAGR) of about 13%. The region benefits from structured pricing policies and hospital tenders that actively push for biosimilar adoption, especially in oncology and rheumatology.

The United States, despite its slower start, is now a heavyweight. The US biosimilars market hit USD 10.9 billion in 2024, according to Alira Health. While this figure is slightly lower than Europe’s current valuation, the growth trajectory is steeper. IMARC Group projects the US market will explode to USD 30.2 billion by 2033, growing at a CAGR of 18.5%. Precedence Research notes an even more aggressive outlook, predicting a 17.50% CAGR from 2025 to 2034.

Why the surge in the US? It’s simple math. The US has a larger pool of high-revenue biologics coming off-patent. IQVIA estimates that 118 biologics will lose patent protection between 2025 and 2034, representing a staggering $232 billion opportunity. As these patents expire, biosimilars step in to capture significant market share, driving revenue up rapidly.

Adoption Rates and Therapeutic Focus

It’s not just about money; it’s about usage. Europe has achieved remarkable penetration rates in specific therapeutic areas. In countries like Germany, France, and the UK, biosimilars have captured over 80% market share in certain oncology and rheumatology treatments. This is due to early implementation of substitution policies and strong physician familiarity. Dr. Michael Reilly from Alira Health noted that Europe’s clear regulatory pathway created a "virtuous cycle" of acceptance among doctors, payers, and patients.

In contrast, the US adoption has been uneven. Initially, biosimilars gained traction mainly in supportive care products like filgrastim (used to boost white blood cell counts during chemotherapy). Complex monoclonal antibodies used for autoimmune diseases saw slower uptake due to litigation fears and lack of interchangeability status. However, this is changing. With the Humira (adalimumab) patent cliff-a blockbuster drug losing exclusivity-the US has seen a flood of approvals. By 2024, 14 Humira biosimilars were approved by the FDA, though only six were commercially available due to patent settlements. As these legal hurdles clear, we expect rapid expansion into immunology and oncology.

Manufacturing and Key Players

Who makes these drugs? The landscape differs by region. Europe is a manufacturing powerhouse, particularly Germany. Coherent Market Insights highlights Germany’s strategic position in the value chain, attracting global developers. Key players dominating the European scene include Sandoz (a Novartis company), Fresenius Kabi, and Amgen. These companies have built robust infrastructure and expertise over nearly twenty years.

The US market features a different set of heavyweights. Pfizer, Merck, and Samsung Bioepis are prominent players. Samsung Bioepis, a joint venture between Samsung Biologics and Amgen, has been instrumental in bringing several key biosimilars to the US market. The US advantage lies in its scale and capital. Companies can invest heavily in large-scale production facilities, knowing that once a product launches, the addressable market is vast. However, they face a fragmented healthcare system where formulary placement decisions vary by private payer, unlike the more centralized procurement systems in Europe.

The Impact of Policy and Legislation

Policy drives progress. In the US, the Inflation Reduction Act of 2022 has been a game-changer. By eliminating the Medicare Part D coverage gap (the "donut hole") and providing incentives for biosimilar adoption, the act removed financial disincentives for seniors to switch to cheaper options. Dr. Sarah Toner from the IQVIA Institute highlighted this as a critical catalyst for market growth.

Europe’s success stems from earlier policy interventions. Many European nations implemented mandatory substitution policies, allowing pharmacists to swap reference biologics for biosimilars without needing a new doctor’s prescription, provided the biosimilar was deemed interchangeable. This streamlined process reduced administrative burden and accelerated patient access. The US is now moving in this direction, with states implementing their own substitution laws and federal agencies encouraging broader use through CMS coverage decisions.

Future Outlook: Convergence or Divergence?

Where do we go from here? The trend points toward convergence. Regulatory harmonization is improving, with both regions accepting similar analytical and non-clinical data requirements. The FDA’s recent moves align closely with EMA practices. Grand View Research forecasts that North America could overtake Europe in market size by 2027, reaching USD 17.2 billion. Meanwhile, Europe continues to grow steadily, projected to reach USD 64.82 billion by 2034.

Challenges remain for both regions. Next-generation biologics are becoming increasingly complex, making similarity harder to demonstrate. Manufacturing these large molecules requires precision and expensive facilities. Additionally, educating physicians and patients remains crucial. Despite evidence of safety and efficacy, some prescribers hesitate to switch established patients. However, the economic pressure is undeniable. Healthcare systems globally are straining under the cost of biologics. Biosimilars offer a proven solution, delivering substantial savings without compromising care quality.

As we move further into 2026, the distinction between the "European model" and the "US model" is blurring. The US is adopting European strategies for regulation and reimbursement, while Europe looks to the US for innovation in complex modalities. For patients, this means better access and lower costs across the Atlantic. For industry players, it means a competitive, dynamic, and lucrative market that rewards agility and scientific rigor.